Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer.


Journal

Cell metabolism
ISSN: 1932-7420
Titre abrégé: Cell Metab
Pays: United States
ID NLM: 101233170

Informations de publication

Date de publication:
06 08 2019
Historique:
received: 11 06 2018
revised: 06 12 2018
accepted: 30 04 2019
pubmed: 28 5 2019
medline: 2 10 2020
entrez: 28 5 2019
Statut: ppublish

Résumé

Cancer stem cells (CSCs) contribute to disease progression and treatment failure in human cancers. The balance among self-renewal, differentiation, and senescence determines the expansion or progressive exhaustion of CSCs. Targeting these processes might lead to novel anticancer therapies. Here, we uncover a novel link between BRD4, mitochondrial dynamics, and self-renewal of prostate CSCs. Targeting BRD4 by genetic knockdown or chemical inhibitors blocked mitochondrial fission and caused CSC exhaustion and loss of tumorigenic capability. Depletion of CSCs occurred in multiple prostate cancer models, indicating a common vulnerability and dependency on mitochondrial dynamics. These effects depended on rewiring of the BRD4-driven transcription and repression of mitochondrial fission factor (Mff). Knockdown of Mff reproduced the effects of BRD4 inhibition, whereas ectopic Mff expression rescued prostate CSCs from exhaustion. This novel concept of targeting mitochondrial plasticity in CSCs through BRD4 inhibition provides a new paradigm for developing more effective treatment strategies for prostate cancer.

Identifiants

pubmed: 31130467
pii: S1550-4131(19)30244-X
doi: 10.1016/j.cmet.2019.05.004
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

303-318.e6

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Gianluca Civenni (G)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Roberto Bosotti (R)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Andrea Timpanaro (A)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Ramiro Vàzquez (R)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Jessica Merulla (J)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Shusil Pandit (S)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Simona Rossi (S)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Domenico Albino (D)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Sara Allegrini (S)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Abhishek Mitra (A)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Sarah N Mapelli (SN)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland; Institute of Computational Science, Università della Svizzera Italiana (USI), Lugano 6900, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne 1015, Switzerland.

Luca Vierling (L)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Martina Giurdanella (M)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Martina Marchetti (M)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Alyssa Paganoni (A)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Andrea Rinaldi (A)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Marco Losa (M)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Enrica Mira-Catò (E)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Rocco D'Antuono (R)

Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Diego Morone (D)

Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Keyvan Rezai (K)

Institute Curie-Hospital René Huguenin, Saint Cloud 92210, France.

Gioacchino D'Ambrosio (G)

IRCCS Multimedica, Milan 20122, Italy.

L'Houcine Ouafik (L)

Aix-Marseille Université, Inserm, Marseille 13007, France.

Sarah Mackenzie (S)

Oncology Therapeutic Development (OTD), Clichy 92110, France.

Maria E Riveiro (ME)

Oncology Therapeutic Development (OTD), Clichy 92110, France.

Esteban Cvitkovic (E)

Oncology Therapeutic Development (OTD), Clichy 92110, France; Oncoethix GmbH, Merck Sharp and Dohme Corp., Lucerne 6006, Switzerland.

Giuseppina M Carbone (GM)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland.

Carlo V Catapano (CV)

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne 1015, Switzerland; Department of Oncology, Faculty of Biology and Medicine, University of Lausanne, Lausanne 1005, Switzerland. Electronic address: carlo.catapano@ior.usi.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH